Clarify Pharma PLC Clarify Pharma Makes First Capital Investment (8186I)

TIDMPSYC

RNS Number : 8186I

Clarify Pharma PLC

17 August 2021

Press Release

17 August 2021

Clarify Pharma PLC

("Clarify Pharma" or the "Company")

First Capital Investment Made

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce a maiden equity investment of approximately US$700,000 into Beckley Psytech Limited ("Beckley Psytech"), a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines.

The investment is being made as part of a Series B fundraising by Beckley Psytech, which is incorporated in the UK, and will give Clarify Pharma a 0.26% interest in the business.

Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Its development programs will focus on offering innovation and clear differentiation in the marketplace over existing treatment options.

Beckley Psytech is supported by an experienced management team and was founded by long-time psychedelic researcher Lady Amanda Feilding and its CEO, Cosmo Feilding Mellen. It has a close strategic partnership with the Beckley Foundation, a renowned non-profit NGO with a 20-year track record of advancing scientific research into psychedelic medicine. Its Scientific Advisory Board includes psychiatric and psychedelic experts such as Dr. Robin Carhart-Harris from Imperial College London, Prof. Matthew Johnson from Johns Hopkins University, Frederick Reinholdt from Kings College London and Prof. Guy Goodwin from the University of Oxford.

Jonathan Bixby, Executive Chairman of Clarify Pharma, said: "Beckley Psytech is a pioneer in psychedelic medicine and we look forward to working with such a reputable company backed by leading figures in this cutting-edge medical field. This investment confirms Clarify Pharma's commitment to support the development of safe alternative therapies to existing mainstream medical practices. We are delighted to be part of a company that is paving the way in this new growth frontier."

Cosmo Feilding Mellen, CEO of Beckley Psytech, said: "We are extremely pleased to welcome Clarify Pharma's investment in Beckley Psytech. This newly raised capital will enable us to realise our long-term vision by further advancing our ambitious research programmes into the development of psychedelics as licensed pharmaceutical treatments for neurological and psychiatric disorders."

For further information please contact:

 
 Clarify Pharma 
 Jon Bixby                             via Tancredi [phone] 
  Executive Chairman 
                                      ------------------------------ 
 First Sentinel 
                                      ------------------------------ 
 Corporate Adviser 
  Brian Stockbridge                    [phone] 
                                      ------------------------------ 
 Tennyson Securities 
                                      ------------------------------ 
 Corporate Broker 
  Peter Krens                          [phone] 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
                                      ------------------------------ 
 Media Relations 
  Catrina Daly 
  Emma Hodges                            [phone] 
  Salamander Davoudi                     [phone] 
  [e-mail]        [phone] 
                                      ------------------------------ 
 

About Clarify Pharma

Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing.

Clarify Pharma is working to assemble a portfolio of companies that focus on the development of psychedelic inspired medicines and experiential therapies for human clinical trials under the supervision and strict adherence to the guidelines of the United Kingdom's MHRA, Canada's Health Canada as well as similar regulatory authorities in other jurisdictions where Clarify or its investee companies operate.

The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.

https://www.clarifypharma.com/

About Beckley Psytech

Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Beckley Psytech's vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks, treatment resistant depression and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, a world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

https://www.beckleypsytech.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXSFWEFMEFSESA

(END) Dow Jones Newswires

August 17, 2021 02:00 ET (06:00 GMT)